Innogen Licenses Efsubaglutide in Selected Emerging Markets

Company Guangzhou Innogen; Arcera Event Type Regional license ($15 million upfront; headline potential above $1 billion) Modality GLP-1 receptor agonist fusion protein Asset Efsubaglutide alfa Target GLP-1 receptor Disease Area Type 2 diabetes Summary Guangzhou Innogen disclosed November 19 a 15-year regional commercialization and development…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *